{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:50:01Z","timestamp":1786981801099,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T00:00:00Z","timestamp":1492041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s11255-017-1591-1","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T04:55:28Z","timestamp":1492059328000},"page":"1111-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients"],"prefix":"10.1007","volume":"49","author":[{"given":"Tong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359\u2013E386","journal-title":"Int J Cancer"},{"issue":"14","key":"1591_CR2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137\u20132150","journal-title":"J Clin Oncol"},{"issue":"4","key":"1591_CR3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572\u2013583","journal-title":"Eur Urol"},{"key":"1591_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1078-1439(01)00155-7","volume":"7","author":"S Lehrer","year":"2002","unstructured":"Lehrer S, Stone N, Droller M, Stock R (2002) Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urol Oncol 7:73\u201376","journal-title":"Urol Oncol"},{"key":"1591_CR5","doi-asserted-by":"crossref","first-page":"978194","DOI":"10.1155\/2015\/978194","volume":"2015","author":"A Peltier","year":"2015","unstructured":"Peltier A, Aoun F, De Ruyter V, Cabri P, Van Velthoven R (2015) Triptorelin in the relief of lower urinary tract symptoms in advanced prostate cancer patients: the result study. Prostate Cancer 2015:978194","journal-title":"Prostate Cancer"},{"key":"1591_CR6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N\u2019dow J, Nordling J, de la Rosette JJ, European Association of Urology (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118\u2013140","journal-title":"Eur Urol"},{"key":"1591_CR7","first-page":"617","volume":"54","author":"W Hamilton","year":"2004","unstructured":"Hamilton W, Sharp D (2004) Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 54:617\u2013621","journal-title":"Br J Gen Pract"},{"key":"1591_CR8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1464-410X.2004.04930.x","volume":"94","author":"SO Andersson","year":"2004","unstructured":"Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE (2004) Prevalence of lower urinary tract symptoms in men aged 45\u201379\u00a0years: a population-based study of 40,000 Swedish men. BJU Int 94:327\u2013331","journal-title":"BJU Int"},{"issue":"12","key":"1591_CR9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.bjc.6604406","volume":"98","author":"E Ream","year":"2008","unstructured":"Ream E, Quennell A, Fincham L, Faithfull S, Khoo V, Wilson-Barnett J, Richardson A (2008) Supportive care needs of men living with prostate cancer in England: a survey. Br J Cancer 98(12):1903\u20131909","journal-title":"Br J Cancer"},{"issue":"4","key":"1591_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/00365599409180520","volume":"28","author":"S Mommsen","year":"1994","unstructured":"Mommsen S, Petersen L (1994) Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J Urol Nephrol 28(4):401\u2013404","journal-title":"Scand J Urol Nephrol"},{"key":"1591_CR11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/00365599.2011.637953","volume":"46","author":"LL Klarskov","year":"2012","unstructured":"Klarskov LL, Klarskov P, Mommsen S, Svolgaard N (2012) Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J Urol Nephrol 46:37\u201343","journal-title":"Scand J Urol Nephrol"},{"issue":"11","key":"1591_CR12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","volume":"110","author":"K Axcrona","year":"2012","unstructured":"Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tank\u00f3 LB, Colli E, Klarskov P (2012) Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int 110(11):1721\u20131728","journal-title":"BJU Int"},{"issue":"6 Suppl","key":"1591_CR13","first-page":"16","volume":"32","author":"M Caine","year":"1988","unstructured":"Caine M (1988) Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology 32(6 Suppl):16\u201320","journal-title":"Urology"},{"issue":"16","key":"1591_CR14","first-page":"4550","volume":"60","author":"N Kyprianou","year":"2000","unstructured":"Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by a1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60(16):4550\u20134555","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"1591_CR15","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/sj.bjp.0706619","volume":"147","author":"MC Michel","year":"2006","unstructured":"Michel MC, Vrydag W (2006) Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147(Suppl 2):S88\u2013S119","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1591_CR16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/j.1939-4640.1991.tb00280.x","volume":"12","author":"JE Oesterling","year":"1991","unstructured":"Oesterling JE (1991) LHRH agonists: a nonsurgical treatment for benign prostatic hyperplasia. J Androl 12(6):381\u2013388","journal-title":"J Androl"},{"issue":"3","key":"1591_CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clon.2012.09.010","volume":"25","author":"M Mason","year":"2013","unstructured":"Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, Bergqvist PB, Khoo V (2013) Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol (R Coll Radiol) 25(3):190\u2013196","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"1591_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-Committee of the International Continence Society (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37\u201349","journal-title":"Urology"},{"key":"1591_CR19","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1742-1241.2007.01491.x","volume":"61","author":"MT Rosenberg","year":"2007","unstructured":"Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, Ohl DA (2007) A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 61:1535\u20131546","journal-title":"Int J Clin Pract"},{"issue":"Suppl A","key":"1591_CR20","first-page":"1","volume":"43","author":"H Momose","year":"2007","unstructured":"Momose H, Hosokawa Y, Kishino T, Ono T, Oyama N (2007) Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs Today (Barc) 43(Suppl A):1\u201310","journal-title":"Drugs Today (Barc)"},{"key":"1591_CR21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2009.03.024","volume":"29","author":"JF Langenhuijsen","year":"2011","unstructured":"Langenhuijsen JF, van Lin EN, Hoffmann AL, Spitters-Post I, Alfred Witjes J, Kaanders JH, Mulders PF (2011) Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol 29:52\u201357","journal-title":"Urol Oncol"},{"key":"1591_CR22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0090-4295(03)00463-1","volume":"62","author":"MV Sanghani","year":"2003","unstructured":"Sanghani MV, Schultz D, Tempany CM, Titelbaum D, Renshaw AA, Loffredo M, Cote K, McMahon B, D\u2019Amico AV (2003) Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology 62:487\u2013491","journal-title":"Urology"},{"issue":"23","key":"1591_CR23","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.100.23.2336","volume":"100","author":"XL Rudner","year":"1999","unstructured":"Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D\u2019Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA (1999) Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 100(23):2336\u20132343","journal-title":"Circulation"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-017-1591-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T11:24:37Z","timestamp":1719141877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-017-1591-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1007\/s11255-017-1591-1","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}